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Abstract
Background: Platinum based therapy is commonly used in the treatment of advanced gastric cancer. However,
resistance to chemotherapy is a major challenge that causes marked variation in individual response rate and
survival rate. In this study, we aimed to identify the expression of GTSE1 and its correlation with cisplatin resistance
in gastric cancer cells.
Methods: Methylation profiling was carried out in tissue samples from gastric cancer patients before undergoing
neoadjuvent therapy using docetaxel, cisplatin and 5FU (DCX) and in gastric cancer cell lines. The correlation
between GTSE1 expression and methylation in gastric cancer cells was determined by RT-PCR and MSP respectively.
GTSE1 expression was knocked-down using shRNA’s and its effects on cisplatin cytotoxicity and cell survival were
detected by MTS, proliferation and clonogenic survival assays. Additionally, the effect of GTSE1 knock down in drug
induced apoptosis was determined by western blotting and apoptosis assays.
Results: GTSE1 exhibited a differential methylation index in gastric cancer patients and in cell lines that correlated
with DCX treatment response and cisplatin sensitivity, respectively. In-vitro, GTSE1 expression showed a direct
correlation with hypomethylation. Interestingly, Cisplatin treatment induced a dose dependent up regulation as
well as nuclear translocation of GTSE1 expression in gastric cancer cells. Knock down of GTSE1 enhanced cisplatin
cytotoxity and led to a significant reduction in cell proliferation and clonogenic survival. Also, loss of GTSE1
expression caused a significant increase in P53 mediated apoptosis in cisplatin treated cells.
Conclusion: Our study identifies GTSE1 as a biomarker for cisplatin resistance in gastric cancer cells. This study also
suggests the repressive role of GTSE1 in cisplatin induced apoptosis and signifies its potential utility as a therapeutic
target for better clinical management of gastric cancer patients.
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Background
Despite of significant advances in therapeutic strategies
and a decline in incidence over the last few decades, gas-
tric cancer still remains as the second most leading
cause of cancer-related mortality worldwide [1, 2].
Currently, surgery represents gold standard for the
treatment of gastric cancer without distant metastasis.
However, chemotherapy appears to be a useful option in
the treatment of advanced gastric cancer, with a modest but
real survival benefit [3]. Platinum based chemotherapy con-
taining cisplatin and oxaliplatin were shown to have prom-
ising results with similar response rate and progression-free
survival (Cunningham et al.; 2008). Although platinum
based therapy is highly active in gastric cancer, a marked
individual variation in response rate (RR) and survival rate
is seen among patients undergoing treatment. In order to
better control the local relapse and increase in survival time
of advanced patients, the role of neoadjuvant chemotherapy
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(NAC) is currently being investigated with different proto-
cols. Multiple phase II and phase III trials utilizing doce-
taxel, cisplatin and 5-FU (DCX) have shown this
combination to be highly effective, particularly in advanced
gastric carcinoma [4, 5]. Albeit these advances, the appear-
ance of drug resistance limits the effectiveness of cancer
chemotherapy and poses a major impediment in clinical
treatment [6]. Earlier studies have revealed the major
mechanisms underlying resistance that include reduced
uptake and/or increased efflux and enhanced DNA repair
[7, 8]. As tumors are highly adaptable, drug resistance can
also be induced by the activation of survival signaling
pathways and the inactivation of downstream death signal-
ing pathways [9]. Additionally, epigenetic changes, changes
in the molecular phenotype and the influence of the local
tumor microenvironment, could also play contributory
roles in chemoresistance [10]. Hence, elucidating the
mechanism underlying the sensitivity and resistance to
chemotherapy is critical to develop a more personalized
approach towards treatment of gastric cancer.
Human GTSE1 (G2 and S phase expressed-1) is
expressed specifically during G2 and S phases of the cell
cycle, and is localized mainly in the cytoplasm, associated
with microtubules [11]. GTSE1 is cell cycle regulated and
becomes phosphorylated in mitosis and markedly reduced
in G1 phase of cell cycle [12]. Over expression of GTSE1
results in a delay of the G2 to M phase transition [13]. The
protein is reported to shuttle between the cytoplasm and
nucleus, however it gets stabilized in the nucleus following
DNA damage. Once in the nucleus, GTSE1 acts as a nega-
tive regulator of p53 expression where it binds and reloca-
lizes p53 to the cytoplasm to undergo degradation [14].
Consequentially, the DNA damage induced trans-
activation of p53 is inhibited, thus affecting p53 induced
apoptosis [14, 15]. In the absence of DNA damage, GTSE1
has been reported to localize to the interphase microtubule
networks where it exists in association with clathrin-
containing complexes [16, 17]. Tian et al. (2011) have
shown that GTSE1 is up-regulated in lung cancer tissues
compared to the adjacent normal tissues, especially in
adenocarcinoma and squamous cell carcinoma. Of interest,
a more than two-fold increase in GTSE1 expression was
shown in myeloma cells after cisplatin treatment, suggest-
ing a mechanism of clinically acquired drug resistance [18].
This study explored the expression, cellular localization
and functional significance of GTSE1 in gastric cancer.
GTSE1 methylation was found to be associated with bet-
ter treatment response to DCX- chemotherapy in gastric
cancer patients. A correlation between GTSE1 expression
and cisplatin cytotoxicity is suggested here, as cisplatin
treatment induced a dose dependent up regulation of
GTSE1 in gastric cancer cells. This increase in expression
was seen associated with a change in cellular localization
as well. Intriguingly, loss of GTSE1 expression contributed
to enhanced cisplatin sensitivity and p53 induced apop-
totic signaling in gastric cancer cells. Taken together, by
identifying the regulatory role of GTSE1 in cisplatin sensi-
tivity and drug induced apoptosis, this study signifies the
potential implications of GTSE1 as a biomarker for
cisplatin resistance in gastric cancer. Moreover, our study
presents an additional candidate for personalised mole-
cular targeted therapy that could overcome cisplatin re-
sistance and thereby attempts to improve the therapeutic
index of this compound in clinical applications.
Methods
Analysis of microarray datasets
Two independent microarray datasets (Gastric cancer: a,
GSE13911; b, GSE27242) of pair wise tumor tissues and
adjacent normal tissues were retrieved from www.oncomi-
ne.org and the mRNA expression level of GTSE1 was in-
vestigated. A total of 169 and 69 samples were analysed in
GSE27242 and GSE27242 respectively.
Patient recruitment and study design
21 consecutive patients with locally advanced [AJCC
TNM (T3/4 or N+ M0)] histologically-proven gastric or
esophagogastric adenocarcinoma with no evidence of
distant metastases, or locally advanced inoperable dis-
ease, as evaluated by computed tomography (CT), chest
radiography, ultrasonography, or laparoscopy were in-
cluded in the study. Pre-treatment characteristics of pa-
tients are mentioned in Table 1. DCX combination was
administered in a 21-day cycle for three cycles before
surgery. The first cohort of 10 patients received intraven-
ous docetaxel 35 mg/m2, intravenous cisplatin 35 mg/m2
on day 1 and day 8, with oral capecitabine 750 mg/m2
twice daily from day 1 to day 14. A subsequent cohort of
another 11 patients had dose modifications to docetaxel
30 mg/m2, cisplatin 30 mg/m2 and capecitabine 700 mg/
m2 due to high rates of diarrhea in the first cohort of 10
patients Preoperative radiological response was evaluable
in 17 patients after two cycles of chemotherapy
(Additional file 1: Figure S1). GTSE1 methylation was
determined in 19 patients prior to neo-adjuvent chemo-
therapy. A total of 14 patients underwent curative surgery
and the surgical details are mentioned in Additional file 1:
Table S1. Seven patients did not undergo surgery with
three having withdrawn consent and two declined surgery
after completing neoadjuvant chemotherapy and two had
disease progression. Eleven patients underwent post
treatment pathological assessment. The median follow-up
was 25 (23–27) months after surgery and patients were
classified as responders or non-responders by the radio-
logical response (Responders: complete response or near-
complete response; Non-responders: partial response or
others). The median follow-up was 25 (23–27) months
after surgery and patients were classified as responders or
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non-responders by the radiological response (Responders:
complete response or near-complete response; Non-
responders: partial response or others). The protocol was
reviewed and approved by the institution’s review board
and informed consent was obtained from each patient.
Ethical approval was obtained from NHG (National
Health Group) Domain Specific Review Board, Singapore.
Genomic methylation profiling
Genomic DNA from primary gastric tissues (11) and cell
lines (39) were bisulphite-modified using EZ DNA
methylation kit (Zymo Research). The modified samples
were profiled in infinium 27 K methylation array
(Illumina). DNA methylation levels for each CpG site
were computed by Genome Studio software as the
ratio of methylated intensity to the sum of methylated
and unmethylated signal intensities.
Cell culture and drug treatment
AZ521 and OCUM-1 were obtained from Japanese Col-
lection of Research Bioresources, Japan. SNU610 and
SNU719 were purchased from Korean Cell Line Bank,
Korea. All the cell lines were cultured at 37 °C in a hu-
midified atmosphere containing 5 % CO2 and maintained
in RPMI 1640 medium (Gibco), containing 10 % heat
inactivated fetal bovine serum (Gibco) and 1 % penicillin/
streptomycin (Gibco). For dose response studies, the cell
lines were treated with cisplatin at IC50 concentration.
Cell Synchronization
Cells were synchronized at the G1/S border by treating
with 2.5 mM thymidine for 16 h followed by extensive
wash and release into normal growth medium for 10 h
to obtain cells in G2/M. The cell cycle stage was moni-
tored by staining with propidium iodide (10 μg/ml),
followed by flow cytometric analysis performed on a
BD™ LSR II (BD biosciences) equipped with FlowJo
software (version vX 0.7).
Quantitative PCR (qPCR) analysis
Total RNA was extracted from cultured cells with
RNeasy Mini kit (Qiagen), with the use of QIAshredder
spin column for homogenization and an on-column
DNase digestion. 2 μg of the total RNA was reversely
transcribed using M-MLV reverse transcriptase enzyme
(Promega). The cDNA obtained was analysed quantita-
tively using Power SYBR Green PCR Master Mix (Ap-
plied Biosystems) on an ABI7300 Real-time PCR system.
Primers used are listed in Table 2. Cycling conditions
were 95 °C for 15 min, 40 cycles of 15 s at 94 °C, 30 s at
55 °C and 30 s at 72 °C. Ct values were generated using
default analysis settings. Relative quantification (RQ) was
calculated using 2 –ΔΔCT method.
Bisulphite conversion and methylation-specific polymerase
chain reaction (MSP)
DNA was extracted from the gastric carcinoma cell lines
with Puregene™ DNA Isolation Kit (Gentra Systems).
500 ng of the cell line DNA, positive control DNA (CpGe-
nome Universal Methylated DNA, Chemicon) and nega-
tive control Human Sperm DNA (HsD) were used for
bisulphate conversion using EZ DNA Methylation-Gold™
Kit (Zymo Research Corporation) as per manufacturer’s
protocol. Primers used for MSP reactions are listed in
Table 3. PCR was performed by preheating at 94 °C for
5 min, then 40 cycles of denaturation at 94 °C for 30 s, an-
nealing at 56 °C/56 °C for 60 s for methylated/unmethy-
lated GTSE1, and extension at 72 °C for 60 s, followed by
a final 7 min extension at 72 °C. The PCR products were
separated on a 2 % agarose gel.
Small hairpin (sh) RNA transfection
Human GTSE1 ‘SureSilencing shRNA’ plasmids were
purchased from Qiagen. AZ521 cells (1 × 10e5 cells/
well) were plated in 6-well plates and grown in 2 ml
RPMI-1640 medium with 10 % FBS. Transfections of
GTSE1 shRNA and control vectors were performed
using X-treme gene transfection reagent (Roche) accord-
ing to the manufacturer’s instructions. Independent
colonies were isolated by ring cloning, and expanded in
1000 μg/ml neomycin. Cell lysates were collected and
GTSE1 expression was detected by western blotting.
Table 1 Pre-treatment characteristics of patients
Pre-treatment characteristics of patients, n = 21
Characteristic
Age
Median (yr) 61 (32–77)
Sex-no. (%)
Male 16 (76.2 %)
Female 5 (23.8 %)
ECOG performance status- no. (%)
0 18 (85.7 %)
1 3 (14.3 %)
Clinical staging (EUS/CT staging)
T1 0 (0 %)
T2 2 (9.5 %)
T3 17 (81.0 %)
T4 2 (9.5 %)
N0 7 (33.3 %)
N+ 14 (66.7 %)
Histology grade
Moderately differentiated 3 (14.3 %)
Poorly differentiated 18 (85.7 %)
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MTS- cell viability assay
To assess the chemosensitivity of tumor cells to cisplatin,
cell viability was measured by MTS (Colorimetric CellTi-
ter 96 Aqueous One Solution Cell Proliferation Assay)
(Promega). Cell suspension was cultured in 96-well flat-
bottomed microtiter plates at seeding density of 2 × 10e3
cells/well and incubated overnight. Drug treatments were
carried out at a dilution range of 0.01-1000 μM cisplatin.
Microtiter wells containing tumour cells with no drug
treatments were used as controls, and wells containing
complete medium were used as blank controls. Cells were
incubated for 72 h before the addition of MTS solution
(1 mg/mL per well) and absorbance was read at 550 nm
using a spectrophotometric microplate reader (Bio-Rad).
The percentage cell viability at different drug concentra-
tions was calculated as the inhibition rate of (mean
absorbance of treated wells/mean absorbance of control
wells) × 100 %. IC50 was calculated by GraphPad Prism
v4.0 (GraphPad Software, Inc).
Cell proliferation (BrdU) assay
Cells were seeded on to 96-well plates at a density of
2 × 103 cells/well. Cell proliferation was measured
using the BrdU proliferation assay (Roche) at 12, 24
and 48 h according to the manufacturer’s protocol.
The absorbance values are directly correlated to the
amount of DNA synthesis.
Colony formation assay
The ability for colony formation at low cell density was
determined by plating 1 × 103 cells/well onto a 6-well
plate and then culturing for 7 days. Cells were subse-
quently stained with 0.5 % crystal violet in 30 % ethanol
and 3 % formaldehyde for 10 min at room temperature.
Stained colonies were counted under the microscope by
selecting a total of five random fields per sample.
Apoptosis assay
Apoptosis was detected by Annexin V-FITC (fluorescein
isothiocyanate) kit (BD Pharmingen) according to manu-
facturer’s instructions. Briefly, the cells (1 × 105 cells/ml)
were grown to 80 % confluency in 25 cm2 flasks in F12K
supplemented with 10 % fetal calf serum. After 24 h of
incubation with or without drug, cells were harvested,
washed thrice with cold PBS and resuspended in 1×
binding buffer. An aliquot of 100 μl of the cell suspen-
sion was transferred into a microfuge tube and mixed
with equal volumes (5 μl) of Annexin V- FITC and Pro-
pidium Iodide (PI). The cells were gently vortexed and
incubated for 15 min at 37 °C in the dark, before the
addition of 400 μl of 1X binding buffer in each tube.
The cell samples were then analysed using a flow
cytometer BD™ LSR II (BD biosciences) equipped with
FlowJo software (version vX 0.7).
Protein extraction and western blot analysis
Cells were washed with ice cold PBS and whole cell lysates
were prepared using CelLytic buffer (Sigma-Aldrich). The
cytoplasmic and nuclear protein fractions were extracted
using NE-PER Nuclear and Cytoplasmic Extraction kit
(Thermo Scientific) as per manufacturer’s instructions.
20 μg of protein was electrophoretically separated on 12 %
SDS-PAGE. Western blots were performed with the pri-
mary antibodies: anti-GTSE1 (Santa Cruz biotechnology),
anti-p53, anti-Bax, anti-p21 Waf1/Cip1 (12D1), anti-
GAPDH (Cell Signaling) and the corresponding secondary
antibodies: anti-rabbit/mouse IgG, HRP-Linked (Cell
Signaling). The signals were visualized by ECL reagent
(Amersham™ ECL Plus Western Blotting Detection
System; GE Healthcare), followed by exposure to chemilu-
minescence film (Amersham Hyperfilm™ ECL; GE Health-
care). Immunoblot analyses were repeated twice for each
protein tested.
Statistical analysis
Two-tailed student’s t-test was used for differential com-
parison between two groups. P value <0.05 was consid-
ered statistically significant. Differential methylation
Table 2 RT PCR primer sequences used to detect GTSE1 mRNA
expression
RT-PCR primers Sequence
GTSE1 forward 5-GCC CCG GGT GCT GTC AAT GT-3
GTSE1 reverse 5-GCC CAC TGC TGG GGA TGT GC-3
GAPDH forward 5′-TGA AGG TCG GAG TCA ACG GAT TTG GT-3
GAPDH reverse 5′-CAT GTG GGC CAT GAG GTC CAC CAC-3′
Table 3 MSP primer sequences used to detect GTSE1 DNA methylation
Methylation/ Unmethylation primers Sequence
Methylated GTSE1 forward 5′-GTA GTG CGT ATG CGT ATT GGA C−3′
Methylated GTSE1 reverse 5′-GCG AAT TAC CGA TTA ATC GAT−3′
Unmethylated GTSE1 forward 5′-AGT AGT GTG TAT GTG TAT TGG ATG−3′
Unmethylated GTSE1 reverse 5′-AAA ACA CAA ATT ACC AAT TAA TCA AT−3′
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analyses between 2 groups were performed using the
statistical package in R (www.r-project.org).
Results
GTSE1 is highly expressed in primary gastric tumours and
correlates with hypomethylation in gastric cancer cells
In order to verify the expression level of GTSE1
mRNA, we analyzed the public microarray database,
Gene Expression Omnibus (Gastric cancer: a,
GSE13911., b, GSE27242). GTSE1 was up-regulated in
both datasets with a fold change of 4.07 and 3.34 and
t-test p-value 7.37E-10 and 1.72E-6 respectively.
Figure 1a shows the log2 transformed fold change of
GTSE1 mRNA level in tumor tissue versus non-
tumor in GSE13911. These findings were further sup-
ported by investigating GTSE1 mRNA expression in
gastric cancer cell lines. As shown in Fig. 1b, GTSE1
expression in 4 gastric cancer cell lines- AZ521,
SNU60, OCUM-1 and SNU719 was analysed by
qPCR. All the cell lines showed detectable expression
of GTSE1 mRNA, among which AZ521 showed a
relatively high GTSE1 expression, whereas SNU 719
showed a relatively low expression. Furthermore, the
association between expression and methylation status
Fig. 1 a GTSE1 Log2 transformed expression level. Fold change of each sample between tumor tissues and non-tumorous tissues in microarray from
GEO in gastric cancer (GSE13911) is shown. b The mRNA expression of GTSE1 in 4 gastric cancer cells detected by qPCR. The gene expression of GTSE1
was normalised relative to GAPDH as internal control. The p value shown for the average data was computed using a paired two-tailed Student t test
(n = 3). Error bars denote standard deviations. c DNA promoter methylation status of MAGE-A1 in 4 gastric cell lines by MSP. UniM: Universal methylated
DNA is the control sample for methylation; HSD: human sperm DNA is the control sample for unmethylation. M: methylation; U: unmethylation
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was determined by MSP (Fig. 1c). A 100 % (4/4) con-
cordance was observed between GTSE1 hypomethyla-
tion and expression as all the cell lines were
unmethylated for GTSE1.
Differential methylation of GTSE1 correlates with
treatment response to DCX and Cispaltin sensitivity
Methylation profiling of tissue samples obtained from 11
GC patients before receiving DCX treatment depicted hy-
pomethylation of GTSE1 (range: 0.03-0.08). GTSE1 was
shown to be differentially methylated in GC patients who
are responders to DCX combinational chemotherapy. Stat-
istical analyses revealed that GC patients who were classi-
fied as responders (n = 3) by pathological response have
significantly higher GTSE1 methylation (T = 4.01, p = 0.04)
as compared to non-responders (n = 8) (Fig. 2a). Similarly,
methylation profiling of 39 GC cell lines also suggested
hypomethylation of GTSE1 (range: 0.01-0.08). Statistical
analyses performed on the top 10 cisplatin-sensitive and
top 10 cisplatin-resistant cell lines revealed significantly
higher GTSE1 methylation in the sensitive cell lines as
compared to the resistant ones (Fig. 2b: T = 3.11, p = 0.006).
Conversely, no association was found between GTSE1
methylation and drug sensitivity of gastric cancer cells to
docetaxel and 5FU (Additional file 1: Figure S2).
GTSE1 knockdown enhanced cisplatin sensitivity in
gastric cancer cells
The association between GTSE1 expression and chemo-
resistance to cisplatin was defined. GTSE1 was stably
knocked-down in AZ521 cells by transfection with tar-
geted shRNA’s. Transfected variants of AZ521 cells
(AZ521-kd) showed a significant reduction in GTSE1 pro-
tein expression compared to the cells transfected with the
scrambled control shRNA (AZ521-cont) and the parental
cell lines (AZ521-p) (Fig. 3a). To detect the role of GTSE1
in chemo resistance, the dose response of AZ521 cells to
cisplatin treatment was analysed. Interestingly, loss of
GTSE-1 expression contributed to enhanced sensitivity to
cisplatin treatment as shown by a ~5 fold decrease in IC50
values of AZ521-kd cells (0.8 μM) compared to the paren-
tal counterpart (3.7 μm) (p = 0.004) (Fig. 3b). The study
suggests GTSE-1 to play a major role in cisplatin resistance
in gastric cancer cells. The drug resistance showed by
GTSE1 expressing cells appeared highly specific to cis-
platin treatment, as similar dose response studies using do-
cetaxel and 5FU in GTSE1 knocked-down cells yielded no
significant variations in IC50 (Additional file 1: Figure S3).
GTSE1 knock down enhanced cisplatin cytotoxicity by
causing a reduction in proliferation and colony formation
of gastric cancer cells
The cytotoxic effects of cisplatin on the proliferation of
AZ521 cells were measured by BrdU cell proliferation
assay (Fig. 4a). Cells pre-treated with cisplatin for 12, 24
and 48 h showed a time dependent reduction in overall
proliferation as compared to the untreated cells. Inter-
estingly, GTSE1 knock down resulted in a greater reduc-
tion in cell proliferation as AZ521-kd cells exhibited a
sharp decline in proliferation within 24 h of cisplatin
treatment (p = 0.01). The results were more significant at
48 h of drug treatment, as observed by a fivefold de-
crease in proliferative cells (p = 0.003). To further con-
firm the enhanced cytototoxic effects of cisplatin in
GTSE1 knock down cells, a clonogenic survival assay
was performed. Although cisplatin treatment induced an
inhibitory effect in the colony formation ability of both
AZ521-con and AZ521-kd cells, the decrease of colony
formation in GTSE1 knocked-down cells appeared to be
Fig. 2 a GTSE1 methylation in gastric cancer patients. Patient
samples were classified as responders or non-responders by
pathological response (Responders: complete response or near-
complete response; Non-responders: partial response or others).
b GTSE1 methylation in gastric cell lines. Differential methylation
analyses were carried out between the top 10 cisplatin resistant
and top 10 cisplatin sensitive groups
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more drastic and highly significant (p = 0.002) as com-
pared to the control cells (Figure 4b). Taken together,
our findings suggest a role of GTSE1 in enhancing the
growth and survivability of gastric cancer cells where it
acts antagonistic to the cellular sensitivity towards
cisplatin.
Cisplatin cytotoxity upregulates GTSE1 expression and
induces its nuclear translocation
Previous studies have shown an increase in GTSE1 ex-
pression in response to DNA damage insults (Monte et
al., [11], [14]). Consistently, the present study observed
a dose dependent up regulation of GTSE1 expression in
cisplatin treated AZ521 cells (Fig. 5a). The expression
levels peaked at close to IC50 concentration of cisplatin.
Moreover, a change in GTSE1 subcellular localization
was also observed as cisplatin treatment induced the
translocation of GTSE1 from the cytoplasm to the
nucleus in a time dependent manner. As shown in Fig. 5b
GTSE1 expression appeared predominantly cytoplasmic
in untreated AZ521 cells. Upon 8 h of cisplatin treat-
ment, a significant reduction in GTSE1 expression was
observed in the cytoplasmic fraction whereas a
corresponding increase in expression was seen in the
nuclear fractions. These findings are in accordance with
and add further credence to the studies by Monte et al.
[14] that showed nuclear accumulation of GTSE1 during
DNA damage.
Fig. 3 a Immunoblot of GTSE1 expression in AZ521 cells. p: parental
cell lines, con: scrambled controls, kd: knockdown variants of GTSE1. At
least two independent experiments were preformed for each cell line.
b MTS assay to determine IC50 of cisplatin (CIS) in AZ521-cont and its
GTSE1 knockdown variant cell line AZ521-kd. Values represent average
of two independent experiments and error bars denote
standard deviations
Fig. 4 a Cell proliferation assay. Proliferation rate of AZ521-con and
AZ521-kd cells as evaluated with the BrdU assay at 12, 24 and 48 h
post cisplatin treatment. Untreated cells served as experimental control.
Results are representative of two independent experiments and error
bars indicate standard deviations. b Clonogenic survival assay. The colony
formation ability of AZ521-con and AZ521-kd cells were measured after
cisplatin treatment. Untreated cells served as experimental control.
Results are representative of two independent experiments and error
bars indicate standard deviations
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GTSE1 expression down regulates cellular apoptosis by
repressing p53 signaling
Studies have shown that p53 expression is up regulated
upon chemotherapeutic stress and GTSE1 was previ-
ously characterised as a negative regulator of p53 (Scolz
et al., [15]; Zhan et al., 2014). This prompted us to fur-
ther investigate the mechanism of cisplatin sensitivity in
GTSE1 knocked-down gastric cancer cells. Treatment of
AZ521 cells with cisplatin caused an up regulation of
p53 expression and its downstream effector bax. Inter-
estingly, knock down of GTSE1 expression lead to a fur-
ther increase in p53 and bax expression levels. This
increase in expression in GTSE1 knock down cells ap-
peared specific to cisplatin cytotoxity as untreated cells
did not show any corresponding variation in p53 and
bax levels (Fig. 6a). Treatment of AZ521 cells with cis-
platin also resulted in caspase 3 cleavage suggesting in-
duction of apoptosis (Additional file 1: Figure S4).On the
other hand, a down regulation in p21 levels was ob-
served in GTSE1 knocked-down cells. This down regula-
tion of p21 converges with the previous shown
functionality of GTSE1, where it prevents proteosome
dependent degradation of p21. Notably, the biological
consequence of p53 upregulation in GTSE1 knocked-
down cells is also reflected by a significant up regulation
in cisplatin induced apoptosis. As shown in Fig. 6b,
GTSE1 knock down enhanced the sensitivity of AZ521
cells to cisplatin treatment resulting in a >50 % increase
in apoptosis compared to the parental cells (p = 0.010).
Discussion
The use of modern genomic, proteomic and functional
analytical techniques has resulted in a substantial in-
crease in our ability to identify novel genes and signaling
networks that are involved in determining the respon-
siveness of tumors to a particular drug treatment. The
mechanisms of resistance to ‘classical’ cytotoxic chemo-
therapeutics and to therapies that are designed to be se-
lective for specific molecular targets share many
features, such as alterations in the drug target, activation
of pro-survival pathways and ineffective induction of cell
death [9]. Pre-clinical and clinical studies have already
shown that combining information from more than one
molecular biomarker increases our ability to predict
tumour drug response [19]. Hence, understanding how
tumors evolve on a molecular level to overcome the
cytotoxic effects of chemotherapy is a critical step in de-
veloping therapeutic approaches that will prevent or
overcome chemoresistance [20].
Alterations in gene expression profiles and epigen-
etic changes are known to be early events in the
multi-steps of carcinogenesis [21]. On an epigenome-
wide basis, multiple DNA methylation changes in the
cancer methylome have been reported to occur dur-
ing the acquisition of drug resistance [22]. Here, we
explored the contributory role of cell cycle dependent
protein GTSE1 in gastric cancer chemoresistance.
GTSE1 is highly expressed in cancers and was shown
to be clinically associated with drug resistance [18].
Analysis of public gene array databases showed high
GTSE1 expression in gastric cancer [23–25]. Since ab-
errant DNA methylation as a marker of platinum-
resistance was shown in lung and ovarian cancer cell
lines [26, 27]; we examined the methylation status of
GTSE1 in gastric cancer patients who underwent neo-
adjuvant DCX-combinational chemo therapy. Although
GTSE1 appeared hypomethylated in both responders and
non responders of DCX treatment, a clear distinction
could be seen between the two groups wherein responders
showed a higher methylation index. However, the current
study was unable to show any significant survival benefit
of GTSE1 methylation in gastric cancer patients. This
could be due to the small sample size and thus hinders
evaluation of GTSE1 methylation as a predictive bio-
marker for DCX treatment response. Consistently, GTSE1
was shown to be hypomethylated in gastric cancer cell
Fig. 5 GTSE1 expression in cisplatin treated AZ521 cells (a) AZ521
cells were treated with varying concentrations of cisplatin. The
whole cell lysates were extracted post 24 h of treatment and GTSE
expression was detected by western blotting. GAPDH served as
loading control (b) GTSE1 sub cellular localization: AZ521 cells were
treated with cisplatin for various time intervals and subcellular
fractions were extracted and blotted for GTSE1 expression. Lamin
and tubulin served as loading controls for nuclear and cytoplasmic
fractions respectively
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lines. All hypomethytlated cell lines showed significant ex-
pression levels of GTSE1. Intriguingly, cell lines that are
sensitive to cisplatin treatment showed a significantly dif-
ferent methylation index for GTSE1. Since, the predomin-
ant model of regulation of gene expression underscores an
inverse correlation between DNA methylation and expres-
sion [28], the higher methylation index of GTSE1 in DCX
responders and in cisplatin sensitive cell lines could be
suggestive of its lower expression levels. However, this
study did not investigate this correlation in the DCX pa-
tient cohort. Hence, clinical implications of GTSE1
methylation status needs further investigation regarding
the possible rationales raised in this study
Gene expression profiling in cancer have provided sub-
stantial information on the oncogenic potential of genes
controlling essential pathways and other cellular events.
Cell proliferation and growth inhibition are tightly regu-
lated processes which are key in the maintenance of normal
cell growth homeostasis and viability [29]. However deregu-
lation of these processes occur during tumor development
and is often contributory to drug resistance. The present
study demonstrated a major role of GTSE1 in conferring
cisplatin resistance as knock down of GTSE1 expression in
gastric cancer cells enhanced cisplatin sensitivity. Moreover,
cisplatin treatment induced a dose dependent upregulation
as well as nuclear translocation of GTSE1 in gastric cancer
cells. The increase in expression and change in membrane
localization of GTSE1 falls in line with a previous study that
showed up regulation and nuclear import of this protein in
response to various DNA- damaging agents [14]. The nu-
clear translocation of GTSE1 is also suggestive of the cellu-
lar response to cisplatin induced DNA damage stress,
where its expression counteracts with drug sensitivity. En-
hanced proliferation and colony formation ability of cells
are well associated with malignant transformation in many
cancers [30]. Although anti-cancer therapy targets apop-
tosis of hyper-proliferative cells, its efficacy may vary ac-
cording to cancers and its molecular sub-types. In our
study, loss of GTSE1 expression enhanced the anti-
proliferative and growth-inhibitory effects of cisplatin in
gastric cancer cells. Of note, the decrease in cell prolifera-
tion and colony formation observed in GTSE1 knocked-
down cells is also suggestive of its tumorogenic potential
that could be utilized in targeted therapies in gastric cancer.
Consistent with these observations, expression of GTSE1
was found inhibitory to cisplatin cytotoxicity as its knock
down lead to a two-fold increase in apoptosis of gastric
cancer cells. This increase in apoptosis could well be ex-
plained by the observed increase of p53 expression in
GTSE1 knocked-down cells. P53 is a potent inhibitor of cell
growth and its function is tightly controlled to allow normal
growth development [31]. In response to DNA damage in-
sults, p53 induces cell cycle arrest and activates the intrinsic
apoptotic signaling pathway [32]. P53 up regulation also re-
sulted in activation of its downstream effectors- bax. This
could attribute to chromatin condensation, DNA fragmen-
tation and finally apoptosis [33]. Hence, up regulation of
p53 and its downstream effectors in cisplatin treated cells
can be inferred as a cellular response to DNA damage.
Therefore, by identifying a reduced expression profile of
p53 in normal cells against GTSE1 knocked-down cells,
our study demonstrates a role of GTSE1 in attenuating p53
mediated apoptotic response in cisplatin treated gastric
cancer cells. However, we did not see any significant differ-
ence in caspase 3 activation in GTSE1 knock down cells
upon cisplatin treatment, as compared to its parental coun-
terparts (Additional file 1: Figure S4). Our findings suggest
that GTSE1 mediates a caspase 3 independent cascade of
apoptotic repression in cisplatin treated gastric cancer cells.
This is consistent with previous studies by and Cui et al.
and Hu et al. that have shown a p53 dependent but caspase
3 independent mechanism of apoptosis [34, 35]. In
addition, GTSE1 expression was also seen to be associated
with high expression of p21 as knockdown of GTSE1
caused a reduction in p21 turn over. This falls in agree-
ment with studies by Bublik et al. that showed GTSE1 as
a regulator of p21 stability by protecting it from
proteosome-dependent degradationEarlier, the association
of GTSE1 with p21 was shown to modulate cellular re-
sponse to paclitaxel induced apoptosis in cervical cancer
cells [36]. Moreover, high levels of p21 in cancers have
been linked to poor prognosis [37]. Thus, by oppositely
regulating p53 and p21, GTSE1 protein may display a com-
bined role in promoting cell survival by shifting the equi-
librium of p53 response from apoptosis to survival [23].
Hence, targeting GTSE1 in cancer therapy could enhance
a p53 mediated pro-apoptotic response with a reflective
decrease in p21 induced cell cycle arrest.
Conclusion
Individualisation of therapy according to the molecular
phenotype of tumour and patient could dramatically in-
crease the effectiveness of chemotherapy. The study pre-
sented here emphasizes the predictive value of GTSE1
(See figure on previous page.)
Fig. 6 Role of GTSE1 in cisplatin induced apoptosis. a AZ521-p, AZ521-con and AZ521-kd cells were treated with cisplatin (5 μm) for 24 h and
expression of pro-apototic p53 and its downstream effectors bax and casp-3 were detected by western blotting. Untreated cells served as experimental
control. GAPDH served as internal control (b) The induction of apoptosis in AZ521-p, AZ521-con and AZ521-kd as detected by flow cytometry using
Annexin V-FITC apoptosis assay. The percentage of apoptotic cells (lower right quadrant) was calculated. Data are presented as the mean values of the
florescent intensities from two independent experiments and error bars standard deviations (SD)
Subhash et al. BMC Cancer  (2015) 15:550 Page 10 of 12
as a biomarker for cisplatin resistance in gastric cancer.
Although previous studies in lung cancer patients did
not show any correlation of GTSE1 with clinical data,
the drug sensitivity profile and down-regulation of p53
induced apoptotic signaling in GTSE1 knocked-down
gastric cancer cells is intriguing and warrants an in
depth analysis of its clinical significance. Future studies
should utilize animal models to further explore the
therapeutic utility of GTSE1 in gastric cancer. Neverthe-
less, our study identifies a previously uncharacterized
role of GTSE1 in conferring cisplatin resistance and pre-
sents an additional avenue for future therapeutic inter-
vention and patient stratification in gastric cancer.
Additional file
Additional file 1: Table S1. Surgical results. Figure S1. Radiological
response after 2 cycles of chemotherapy (n = 17). Figure S2. GTSE1
methylation in gastric cell lines (a) Differential methylation analyses were
carried out between the top docetaxel resistant and docetaxel sensitive
groups. (b) Differential methylation analyses were carried out between
the top 5FU resistant and 5FU sensitive groups. Figure S3. MTS assay to
determine IC50 of (a) docetaxel (DOC) and (b) 5FU in AZ521-cont and its
GTSE1 knockdown variant cell line AZ521-kd. Values represent average of
two independent experiments and error bars denote standard deviations.
Figure S4. Caspase 3 cleavage in cisplatin treated AZ521 cells. a) AZ521-p,
AZ521-con and AZ521-kd cells were treated with cisplatin (5 μm) for 24 h and
caspase 3 expression was detected by western blotting. Untreated cells served
as experimental control. GAPDH served as loading control. (DOC 710 kb)
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